Corrected Announcement Follows
NEW YORK, Oct. 2 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that I. Craig Henderson, MD, the Company's President, will present an overview of the Company's cancer pipeline at the upcoming William Blair & Company Small-Cap Growth Stock Conference in New York City. Dr. Henderson's presentation will take place on Wednesday, October 3rd at 12:00 noon ET.
Dr. Henderson's presentation will be webcast live and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition,
development and commercialization of medically important, novel
pharmaceutical products for the treatment of life-threatening diseases,
including diabetes and cancer. Keryx's lead compound under development is
Sulonex(TM) (sulodexide), previously referred to as KRX-101, a
first-in-class, oral heparinoid compound for the treatment of diabetic
nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex
is in a pivotal Phase III and Phase IV clinical program under a Special
Protocol Assessment with the Food & Drug Administration. Additionally,
Keryx is developing Zerenex(TM), an oral, iron- based compound that has the
capacity to bind phosphate and form non-absorbable complexes. Zerenex is
currently in Phase II clinical development for the treatment of
hyperphosphatemia (elevated serum phosphorous levels) in patients with
end-st
'/>"/>
| SOURCE Keryx Biopharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |